Noninvasive detection of clinically occult lymph-node metastases in prostate cancer

New England Journal of Medicine

Volumn 348, Issue 25, 2003, Pages 2491-2499

  Harisinghani, Mukesh G ^a   Barentsz, Jelle ^b   Hahn, Peter F ^a   Deserno, Willem M ^b   Tabatabaei, Shahin ^a   Van de Kaa, Christine Hulsbergen ^b   De la Rosette, Jean ^b   Weissleder, Ralph ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; NANOPARTICLE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ADULT; AGED; ARTICLE; BODY WEIGHT; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; HISTOPATHOLOGY; HUMAN; LEYDIG CELL; LOW BACK PAIN; LYMPH; LYMPH NODE METASTASIS; LYMPHADENECTOMY; LYMPHOTROPIC SUPERPARAMAGNETIC NANOPARTICLE; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCULT CANCER; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

AGED; BIOPSY; CONTRAST MEDIA; FERRIC COMPOUNDS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LYMPH NODES; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MAGNETICS; MALE; MIDDLE AGED; NANOTECHNOLOGY; NEOPLASM STAGING; PARTICLE SIZE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 0038469746     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa022749     Document Type: Article

References (35)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36. [Erratum, CA Cancer J Clin 2001;51:144.]
2. Walsh PC. Surgery and the reduction of mortality from prostate cancer. N Engl J Med 2002;347:839-40.
3. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345:948-55.
4. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781-8.
5. Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347:781-9.
6. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339:1036-42.
7. D'Amico AV, Cormack RA, Tempany CM. MRI-guided diagnosis and treatment of prostate cancer. N Engl J Med 2001;344:776-7.
8. Brinkmann AO, Trapman J. Prostate cancer schemes for androgen escape. Nat Med 2000;6:628-9.
9. Cheng L, Bergstralh EJ, Cheville JC, et al. Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am J Surg Pathol 1998;22:1491-500.
10. Kothari PS, Scardino PT, Ohori M, Kattan MW, Wheeler TM. Incidence, location, and significance of periprostatic and periseminal vesicle lymph nodes in prostate cancer. Am J Surg Pathol 2001;25:1429-32.
11. Tempany CM, McNeil BJ. Advances in biomedical imaging. JAMA 2001;285:562-7.
12. Kurhanewicz J, Vigneron DB, Males RG, Swanson MG, Yu KK, Hricak H. The prostate: MR imaging and spectroscopy: present and future. Radiol Clin North Am 2000;38:115-38.
13. Hricak H, Dooms GC, Jeffrey RB, et al. Prostatic carcinoma: staging by clinical assessment, CT, and MR imaging. Radiology 1987;162:331-6.
14. Katz-Brull R, Lavin PT, Lenkinski RE. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J Natl Cancer Inst 2002;94:1197-203.
15. Weissleder R, Moore A, Mahmood U, et al. In vivo magnetic resonance imaging of transgene expression. Nat Med 2000;6:351-5.
16. Weissleder R, Elizondo G, Wittenberg J, Lee AS, Josephson L, Brady TJ. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 1990;175:494-8.
17. Lewin M, Carlesso N, Tung CH, et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 2000;18:410-4.
18. Perez JM, Josephson L, O'Loughlin T, Hogemann D, Weissleder R. Magnetic relaxation switches capable of sensing molecular interactions. Nat Biotechnol 2002;20:816-20.
19. Harisinghani MG, Saini S, Weissleder R, et al. MR lymphangiography using ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: radiographic-pathologic correlation. AJR Am J Roentgenol 1999;172:1347-51.
20. Wunderbaldinger P, Josephson L, Bremer C, Moore A, Weissleder R. Detection of lymph node metastases by contrast-enhanced MRI in an experimental model. Magn Reson Med 2002;47:292-7.
21. Link RE, Morton RA. Indications for pelvic lymphadenectomy in prostate cancer. Urol Clin North Am 2001;28:491-8.
22. Begg CB, Riedel ER, Bach PB, et al. Variations in morbidity after radical prostatectomy. N Engl J Med 2002;346:1138-44.
23. Shen T, Weissleder R, Papisov M, Bogdanov A, Brady T. Monocrystalline iron oxide nanocompounds (MION): physiochemical properties. Magn Reson Med 1993;29:599-604.
24. Jager GJ, Barentsz JO, Oosterhof GO, Witjes JA, Ruijs SJ. Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional T1-weighted magnetization-prepared-rapid gradient-echo sequence. AJR Am J Roentgenol 1996;167:1503-7.
25. Metz CE. ROC methodology in radiologic imaging. Invest Radiol 1986;21:720-33.
26. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
27. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. JAMA 1997;277:1445-51. [Erratum, JAMA 1997;278:118.]
28. Beissner RS, Stricker JB, Speights VO, Coffield KS, Spiekerman AM, Riggs M. Frozen section diagnosis of metastatic prostate adenocarcinoma in pelvic lymphadenectomy compared with nomogram prediction of metastasis. Urology 2002;59:721-5.
29. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
30. Anzai Y, Blackwell KE, Hirschowitz SL, et al. Initial clinical experience with dextran-coated superparamagnetic iron oxide for detection of lymph node metastases in patients with head and neck cancer. Radiology 1994;192:709-15.
31. Stets C, Brandt S, Wallis F, Buchmann J, Gilbert FJ, Heywang-Kobrunner SH. Axillary lymph node metastases: a statistical analysis of various parameters in MRI with USPIO. J Magn Reson Imaging 2002;16:60-8.
32. Pannu HK, Wang KP, Borman TL, Bluemke DA. MR imaging of mediastinal lymph nodes: evaluation using a superparamagnetic contrast agent. J Magn Reson Imaging 2000;12:899-904.
33. Michel SC, Keller TM, Frohlich JM, et al. Preoperative breast cancer staging: MR imaging of the axilla with ultrasmall superparamagnetic iron oxide enhancement. Radiology 2002;225:527-36.
34. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Visualization of prostate cancer with 11C-choline postiron emission tomography. Eur Urol 2002;42:18-23.
35. Campbell SC, Klein EA, Levin HS, Piedmonte MR. Open pelvic lymph node dissection for prostate cancer: a reassessment. Urology 1995;46:352-5.